Priority Essential Medicines for Child Survival, September 2010
UNICEF in collaboration with the World Health Organisation focusing on essential medicines
Since 2006, a lot of work has gone into identifying essential medicines for children and optimal paediatric dosage forms in general. The first WHOModel List of Essential Medicines for children was published in 2007, and the second in March 2009. The first Model Formulary for Children is available since June 2010. http://www.who.int/selection_medicines/list/en/
This is an opportune time to focus on those essential medicines that will contribute to child survival gains. What are the optimal dosage forms, dosage strengths and pack sizes of these products? What can be done to ensure the manufacture and supply of quality products to be made available at the point of care?
The purpose of this meeting was to bring together experts, stakeholders and representative beneficiary countries to evaluate existing information, come to an agreement on what the priority essential medicines for child survival are and work out a preliminary plan to ensure their availability and affordability. The disease focus areas are Pneumonia, Diarrhoea, Malaria, Neonatal Sepsis, HIV treatment and prevention, Opportunistic Infection prophylaxis, Tuberculosis and Pain Management.
1. Agreement on the priority essential medicines for child survival
2. Agreement on specifications for these medicines; the desired dosage forms, strengths and pack sizes
3. Identification of specific product gaps
4. A plan to fill the gaps in terms of new products, new formulations and potential sources.
The outcomes will become the basis for deliberations with the pharmaceutical industry, drug regulators, policy makers and implementers to make these priority essential medicines available and affordable. In the short term, it will inform the key messages to manufacturers at the UNICEF Pharmaceutical manufacturers meeting scheduled for 27 and 28 September 2010, which will also take place at UNICEF Supply Division in Copenhagen.
Qazi Shamin Ahmed - WHO - Child and Adolescent Health, Suzanne Hill - WHO - Essential Medicines and Policy (EMP), Kelita Kamoto - Malawi - Product Characteristics, Perspectives from Community Health Workers in Malawi, Carine Werder - MSF, Paediatric Medicines MSF field experiences, Tony Nunn - Dosage form issues and gaps, Alexis Heaton - The Supply Chain Perspective, Marcel de Matas - UK - Formulating Drug Products for Children, Tom Sam - IFPMA - R&D Pharmaceutical Industry Perspective on Specifications for Pediatric Medicines, Christine Strunz Lehner - Developing paediatric medication
David Rupin - Clinton foundation - Challenges and Barriers to Access, Francisco Blanco - UNICEF - Sources and Prices of selected medicines for children, Penny Grewal Daumeri - MMV -Increasing the supply base of paediatric antimalarials, Susan D. Foster - Tufts Uni - Antibiotic resistance issues in Uganda, Henrik Nielsen - UNICEF - Customization - Procurement process of tracer medicines, Nathalie Seigneuret - EMA - Regulatory incentives Experience from EMA, Lembit Rägo - Prequalification of Medicines Programme, Suzanne Hill - WHO-UNICEF, What do we need? The WHO/UNICEF wish list, Ahmet Afsar - UNICEF - Community case management experience, Angus Spiers - PSI - Social Marketing Approaches to Child Survival
For further information please contact Atieno Ojoo under firstname.lastname@example.org